Docket No.: 50179-086

- IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

th re Application of

Group Art Unit: 1631

Thomas C. Elleman et al.

Examiner: M.B. SHEINBERG

Serial No.: 09/701,437

Filed: March 2, 2001

For: METHOD OF DESIGNING AGONISTS AND ANTAGONISTS TO EGF RECEPTOR FAMILY

THE ASSISTANT COMMISSIONER FOR PATENTS Washington, DC 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.

No additional fee is required.

Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified

statement previously submitted.

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

Also attached:

The fee has been calculated as shown below:

| | NO. OF CLAIMS | HIGHEST PREVIOUSLY PAID FOR | EXTRA CLAIMS | RATE | FEE · |
|---------------------------|------------------|-----------------------------------|-----------------|-----------|--------|
| Total Claims | 26 | 53 | 0 | \$18.00 = | \$0.00 |
| Independent Claims | 1 | 3 | 0 | \$84.00 = | \$.00 |
| | | Multiple claims newly presented | | | \$0.00 |
| Fee for extension of time | | | | \$0.00 | |
| | | | | | |
| | | Total of Above Calculations | | | \$0.00 |

Please charge my Deposit Account No. 50-0417 in the amount \$. An additional copy of this \boxtimes transmittal sheet is submitted herewith.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication \boxtimes or credit any overpayment, to Deposit Account No. <u>500417</u>, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

McDERMOTT, WILL & EMERY

Judith L. Toffenetti

Registration No. 39,048

600 13th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 RLP/JLT/rp

Date: June 11, 2002 Facsimile: (202) 756-8087 ATTORNEY DOCKET NO. 50179-086
PATENT

In re Application of:

Thomas C. Elleman et al.

Serial No.: 09/701,437

Filed: March 2, 2001

For: METHOD OF DESIGNING AGONISTS AND ANTAGONISTS TO EGF RECEPTOR FAMILY)

AMENDMENT AND REPLY

Hon. Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 11,920029h #WHY a Shortened of the calculation statutory period for response set to expire June 11, 20029 please amend the cabove-identified application as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 11, line 13, with the following rewritten paragraph:



--Figure 6: Coordinates of the two models of the EGF receptor extracellular domain. The first model (6A-1 through top half of 6A-32) consists of the domains L1 and S1. The second model (6A-32 (bottom half) through 6B-31) consists of the domains